drugset

drugset / Trial / NCT07062588

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

NCT07062588 ↗

Phase 2 Recruiting 80 enrolled Angitia Incorporated Limited

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.

Timeline

Start: 2025-12-12
Primary completion: 2027-11
Completion: 2029-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AGA2115	Unknown	—	Subcutaneous

Indications